HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Study of PF-06873600 in People With Cancer (NCT03519178) | Pfizer | 2018-03-07 |
Track HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.